|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM371672201 |
| 003 |
DE-627 |
| 005 |
20240720232800.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240428s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202402570
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1476.xml
|
| 035 |
|
|
|a (DE-627)NLM371672201
|
| 035 |
|
|
|a (NLM)38678378
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Cevik, Enes
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Catheter-Directed Ionic Liquid Embolic Agent for Rapid Portal Vein Embolization, Segmentectomy, and Bile Duct Ablation
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.07.2024
|
| 500 |
|
|
|a Date Revised 20.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 The Authors. Advanced Materials published by Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Embolic materials currently in use for portal vein embolization (PVE) do not treat the tumor, which poses a risk for tumor progression during the interval between PVE and surgical resection. Here, is developed an ionic-liquid-based embolic material (LEAD) for portal vein embolization, liver ablation, and drug delivery. LEAD is optimized and characterized for diffusivity, X-ray visibility, and cytotoxicity. In the porcine renal embolization model, LEAD delivered from the main renal artery reached vasculature down to 10 microns with uniform tissue ablation and delivery of small and large therapeutics. In non-survival and survival porcine experiments, successful PVE is achieved in minutes, leading to the expected chemical segmentectomy, and delivery of a large protein drug (i.e., Nivolumab) with LEAD. In cholangiocarcinoma mouse tumor models and in ex vivo human tumors, LEAD consistently achieved an effective ablation and wide drug distribution. Furthermore, various strains of drug-resistant patient-derived bacteria showed significant susceptibility to LEAD, suggesting that LEAD may also prevent infectious complications resulting from tissue ablation. With its capabilities to embolize, ablate, and deliver therapeutics, ease of use, and a high safety profile demonstrated in animal studies, LEAD offers a potential alternative to tumor ablation with or without PVE for FLR growth
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a ablation
|
| 650 |
|
4 |
|a drug delivery
|
| 650 |
|
4 |
|a embolization
|
| 650 |
|
4 |
|a immunotherapy
|
| 650 |
|
4 |
|a portal vein
|
| 650 |
|
7 |
|a Ionic Liquids
|2 NLM
|
| 700 |
1 |
|
|a Albadawi, Hassan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Zefu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Demirlenk, Yusuf
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Atar, Dila
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Keum, Chris
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Jinjoo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Graf, Erin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gunduz, Seyda
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rehman, Suliman
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Oklu, Rahmi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 29 vom: 01. Juli, Seite e2402570
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:29
|g day:01
|g month:07
|g pages:e2402570
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202402570
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 29
|b 01
|c 07
|h e2402570
|